1. Clinical & Scientific Overview
Acitretin (TIP-MED-000546, Reference Code [R-27]) is classified under
Dermatology (Severe Keratinisation Disorders) as a Second-Generation Systemic Aromatic Retinoid.
Within the Indian regulatory and compendial framework, it is governed under Schedule H + Mandatory 3-Year Post-Therapy Teratogen Contraception.
Acrotac (Sun Pharmaceutical Industries), Aceret (Glenmark Pharmaceuticals), Actoid (Intas Pharmaceuticals)
Hard Gelatin Capsule: 10 mg, 25 mg
Statutory Restriction, High-Alert & Dispensing Safeguards
Indian Regulatory & Statutory Control Basis: Schedule H + Mandatory 3-Year Post-Therapy Teratogen Contraception
High-Alert Clinical Risk, Dependence & Narrow Therapeutic Index Warnings: CRITICAL PHARMACOKINETIC TERATOGEN TRAP: Although acitretin itself has a half-life of ~50 hours, in the presence of ethanol (alcohol in beverages, foods, or medicines) it undergoes reverse esterification in vivo to etretinate, which is sequestered in subcutaneous adipose tissue with a terminal half-life of 120 DAYS — therefore pregnancy and blood donation are strictly contraindicated during therapy and for 3 FULL YEARS after stopping acitretin!
Mandatory Dispensing Register & Institutional Custody Protocol: Counsel female patients of childbearing potential to avoid ALL alcohol during therapy and for 2 months after stopping, and to maintain strict contraception and avoid blood donation for 3 years post-discontinuation.
3. Mechanism of Action & Pharmacodynamics
Activates nuclear retinoic acid receptors (RAR-alpha, beta, gamma), normalising epidermal keratinocyte proliferation, differentiation, and cornification in psoriasis.
4. Therapeutic Indications & Evidence-Supported Uses
- Severe generalized pustular, erythrodermic, or recalcitrant plaque psoriasis
- Congenital ichthyosis and Darier disease
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Specialist-Supervised Educational Reference Summary: Dosing of Acitretin must be individualised by a qualified specialist according to clinical indication, organ function, and institutional protocol (Hard Gelatin Capsule: 10 mg, 25 mg).
Administration & Meal Timing: Routes: Oral (once daily with a main meal or milk). Counsel female patients of childbearing potential to avoid ALL alcohol during therapy and for 2 months after stopping, and to maintain strict contraception and avoid blood donation for 3 years post-discontinuation.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Exhibits second-generation systemic aromatic retinoid pharmacokinetic disposition; verify baseline renal and hepatic clearance and check for active or prolonged-half-life metabolites before repeat dosing.
Hepatic Phase I (CYP450) and/or Phase II conjugation or specific non-renal clearance as detailed in clinical warnings.
Verify eGFR / CrCl before initiation; see specific metabolite and renal clearance notes above.
Assess baseline Child-Pugh status and hepatic transaminases prior to therapy.
7. Contraindications, Precautions & High-Risk Warnings
- Known severe hypersensitivity to Acitretin or formulation excipients
- Unsupervised outpatient self-administration or dispensing without mandatory statutory prescription verification
- Specific clinical contraindications detailed under High-Alert Warnings & Statutory Restrictions
Key Clinical Precautions: CRITICAL PHARMACOKINETIC TERATOGEN TRAP: Although acitretin itself has a half-life of ~50 hours, in the presence of ethanol (alcohol in beverages, foods, or medicines) it undergoes reverse esterification in vivo to etretinate, which is sequestered in subcutaneous adipose tissue with a terminal half-life of 120 DAYS — therefore pregnancy and blood donation are strictly contraindicated during therapy and for 3 FULL YEARS after stopping acitretin!
8. Adverse Effects Profile
- CRITICAL PHARMACOKINETIC TERATOGEN TRAP: Although acitretin itself has a half-life of ~50 hours, in the presence of ethanol (alcohol in beverages, foods, or medicines) it undergoes reverse esterification in vivo to etretinate, which is sequestered in subcutaneous adipose tissue with a terminal half-life of 120 DAYS — therefore pregnancy and blood donation are strictly contraindicated during therapy and for 3 FULL YEARS after stopping acitretin!
- Dose-dependent target-organ pharmacodynamic effects requiring clinical observation
- CRITICAL PHARMACOKINETIC TERATOGEN TRAP: Although acitretin itself has a half-life of ~50 hours, in the presence of ethanol (alcohol in beverages, foods, or medicines) it undergoes reverse esterification in vivo to etretinate, which is sequestered in subcutaneous adipose tissue with a terminal half-life of 120 DAYS — therefore pregnancy and blood donation are strictly contraindicated during therapy and for 3 FULL YEARS after stopping acitretin!
- High-alert toxicity, dependence/diversion risk, or severe organ-specific adverse events if administered outside protocol
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CRITICAL PHARMACOKINETIC TERATOGEN TRAP: Although acitretin itself has a half-life of ~50 hours, in the presence of ethanol (alcohol in beverages, foods, or medicines) it undergoes reverse esterification in vivo to etretinate, which is sequestered in subcutaneous adipose tissue with a terminal half-life of 120 DAYS — therefore pregnancy and blood donation are strictly contraindicated during therapy and for 3 FULL YEARS after stopping acitretin!
- Review all concomitant CNS depressants, QTc-prolonging agents, nephrotoxins, or CYP450 modulators prior to dispensing.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Counsel female patients of childbearing potential to avoid ALL alcohol during therapy and for 2 months after stopping, and to maintain strict contraception and avoid blood donation for 3 years post-discontinuation.
Pharmacist Patient Counselling Points:
- Counsel female patients of childbearing potential to avoid ALL alcohol during therapy and for 2 months after stopping, and to maintain strict contraception and avoid blood donation for 3 years post-discontinuation.
- Must be used strictly under direct medical supervision; never share prescription medicines or alter the prescribed dose.
Storage, Stability & Dispensing Safeguards: Counsel female patients of childbearing potential to avoid ALL alcohol during therapy and for 2 months after stopping, and to maintain strict contraception and avoid blood donation for 3 years post-discontinuation.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Drugs and Cosmetics Act, 1940 & Rules, 1945 (Schedule H / H1 / X); NDPS Act, 1985 & Essential Narcotic Drugs (END) Notification; Indian Pharmacopoeia (IP) & National Formulary of India (NFI).
Official Verification Portals: CDSCO — Drugs & Cosmetics Act and Rules (Schedules H, H1, X) • Department of Revenue — Narcotic Drugs and Psychotropic Substances (NDPS) Act • Indian Pharmacopoeia Commission (IPC) — National Formulary of India
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.